Despite relevant advances in survival rates of pediatric acute lymphoblastic leukemia (ALL), in adult patients the outcome is still dismal because of a greater drug resistance, a poorer compliance with treatment, and less effective current therapies. The need for more active agents has identified a novel purine nucleoside analogue, clofarabine, which has been approved for the treatment of children with relapsed and refractory ALL, showing also promising clinical benefit in phase III studies in adult patients.
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia / C. Papayannidis, E. Derenzini, I. Iacobucci, A. Curti, S. Paolini, D. Cilloni, M. Baccarani, G. Martinelli. - In: AMERICAN JOURNAL OF HEMATOLOGY. - ISSN 0361-8609. - 84:12(2009), pp. 849-850. [10.1002/ajh.21548]
Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia
E. Derenzini;
2009
Abstract
Despite relevant advances in survival rates of pediatric acute lymphoblastic leukemia (ALL), in adult patients the outcome is still dismal because of a greater drug resistance, a poorer compliance with treatment, and less effective current therapies. The need for more active agents has identified a novel purine nucleoside analogue, clofarabine, which has been approved for the treatment of children with relapsed and refractory ALL, showing also promising clinical benefit in phase III studies in adult patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
ajh.21548.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
115.93 kB
Formato
Adobe PDF
|
115.93 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
